Curasight A/S, a pioneering company in cancer diagnostics and treatment, has announced a rights issue aimed at raising approximately DKK 100 million in gross proceeds. This strategic move is designed to bolster the company's financial standing, supporting its innovative theranostic approach to cancer treatment through its uTRACE® and uTREAT® platforms.

The rights issue, if fully subscribed, will provide Curasight with the necessary capital to continue its ambitious development programs. The funds are expected to cover the completion of the Phase II trial for uTRACE® in prostate cancer and the Phase I trial for uTREAT® in brain cancer, among other strategic initiatives.

CEO Ulrich Krasilnikoff expressed optimism about the future, highlighting the strategic partnership with Curium, a global leader in nuclear medicine. This partnership validates Curasight's theranostic approach and enhances its capabilities in delivering precise cancer diagnostics and treatments.

In terms of financial strategy, the rights issue is supported by significant commitments from key partners like Curium and Pentwater, alongside guarantee commitments from external investors. This robust backing underscores confidence in Curasight's innovative platforms and strategic direction.

For investors, the rights issue presents an opportunity to participate in a company at the forefront of cancer treatment innovation. Given the strong backing and strategic partnerships, the recommendation is to hold current investments in Curasight, as the potential for growth and value creation remains significant.